CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer

Abstract excerpt

The inhibitor of CDK4/6 has been clinically used for treating certain types of cancer which are characterized by G0/G1 acceleration induced by the CDK4/6-RB1 pathway. On the contrary, the cell cycle–related molecules are abnormal in over 50% of the patients with gastric cancer (GC), but the efficiency of inhibiting CDK4/6 does not work well as it is expected. In our study, we found HMGA2 promotes GC through...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Cancer Genomics and Diagnostics
• Share to Cancer-related Molecular Pathways